A Nonrandomized Phase 2 Trial of EG-Mirotin, a Novel, First-in-Class, Subcutaneously Deliverable Peptide Drug for Nonproliferative Diabetic Retinopathy

<i>Background and objectives:</i> EG-Mirotin (active ingredient EGT022) targets nonproliferative diabetic retinopathy (NPDR), the early stage of retinopathy. EG-Mirotin reverses capillary damage before NPDR progresses to an irreversible stage. EG-Mirotin safety and efficacy were investig...

Full description

Bibliographic Details

Published in:	Medicina
Main Authors:	Seunghoon Yoo, Dae Hyuk You, Jeongyoon Lee, H. Christian Hong, Sung Jin Lee
Format:	Article
Language:	English
Published:	MDPI AG 2023-01-01
Subjects:	diabetic retinopathy nonproliferative diabetic retinopathy retinal ischemia
Online Access:	https://www.mdpi.com/1648-9144/59/1/178